Eli Lilly developed the diabetes drug Mounjaro and trades under the ticker LLY.
Eli Lilly and Company was founded in Indianapolis in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Civil War veteran. The company initially focused on producing medicines with consistent quality and dosage, an important distinction in an era when drug contents could vary widely.
Mounjaro is the brand name for tirzepatide, which the U.S. Food and Drug Administration approved in 2022 for improving blood-sugar control in adults with type 2 diabetes. Tirzepatide acts on two hormone pathways involved in glucose regulation and appetite. Its separate obesity-treatment brand is Zepbound.
Mounjaro is therefore not the same product as insulin, Ozempic, or Wegovy. Ozempic and Wegovy contain semaglutide and are made by Novo Nordisk, while Mounjaro and Zepbound contain tirzepatide and are made by Eli Lilly. Eli Lilly’s rising drug revenue helped make it one of the world’s most valuable pharmaceutical companies.